Hematotoxicity of intratracheally instilled arsenic trioxide in rats

Objective: The study aimed to investigate the correlation between concentration of inhaled arsenic trioxide and dynamic changes in hematotoxicity in rats. Method: Wistar rats were randomly divided into four study groups that were treated with saline(control) or arsenic trioxide at a low(0.1 mg/mL), medium(1 mg/mL), or high(10 mg/mL) dose by intratracheal instillation. Blood samples were collected for analysis at 6, 12, 24, 48, and 72 h after exposure. Results: Compared with the control group, the red blood cell distribution width decreased significantly in each exposure group and then gradually recovered. The red blood cell count only increased in the high-dose group, and the hemoglobin levels did not differ significantly between the groups. Significant decreases in the platelet count and mean platelet volume were observed in each arsenic-exposed group. White blood cell countsalso decreased significantly and then gradually recovered; this was associated with an increased percentage of lymphocytes and a decreased percentage of neutrophils. The blood cell parameter changes were related to the arsenic trioxide concentration and the observation time. Conclusion: Intratracheal instillation of arsenic trioxide affected hematopoietic differentiation in rats, leading to blood cell changes that were related to observation time and concentration.

Effects of endostatin combined with pemetrexed and cisplatin on the levels of TNF-α, NSE, CEA, CA199, AFP and CYFRA21-1 in patients with advanced lung adenocarcinoma

Objective: To investigate the effect of endostatin combined with pemetrexed and cisplatin on the levels of TNF-α, NSE, CEA, CA199, AFP and CYFRA21-1 in patients with advanced lung adenocarcinoma. Methods: The retrospective analysis method was used to analyse the 80 patients with advanced adenocarcinoma of the lung in our hospital from January 2013 to January 2017, and patients were divided into two groups: the control group and the observation group. The patients in the control group received pemetrexed combined with cisplatin on the basis of conventional treatment, the observation group was treated with endostatin on the basis of the treatment of the control group, then the changes of TNF-α, NSE, CEA, CA199, AFP and CYFRA21-1 levels in two groups before and after treatment (3 cycles of chemotherapy) were detected and compared. Results: Before treatment, there was no significant difference in serum TNF-α, NSE, CEA, CA199, AFP and CYFRA21-1 levels between the two groups;After treatment, the levels of TNF-α, NSE, CEA, CA199, AFP and CYFRA21-1 in the control group were (5.58±2.43) pg/mL, (17.65±6.97) ng/mL, (6.13±1.14) ng/mL, (62.48±7.86) U/mL, (15.28±4.17) ng/mL, (2.81±0.54) ng/mL, that in the observation group were (4.37±2.15) pg/mL, (11.33±5.24) ng/mL, (4.65±0.88) ng/mL, (51.71±5.23) U/mL, (10.29±3.56) ng/mL, (1.74±0.23) ng/mL, Compared with the same group before treatment, the level of indicators were significantly improved, the difference was statistically significant, and The improvement of the indexes in the observation group was obviously better than that in the control group, and the difference was statistically significant. Conclusion: With the use of pemetrexed and cisplatin in the treatment of advanced lung adenocarcinoma patients, the addition of endostatin could improve the levels of serum TNF-α, NSE, CEA, CA199, AFP and CYFRA21-1 in patients with advanced lung adenocarcinoma, To some extent, it shows that the combined use of drugs is more effective and is worthy of further clinical research and application.